DOCSLIB.ORG

A Review of Melioidosis Cases Imported Into Europe

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Review of Melioidosis Cases Imported Into Europe European Journal of Clinical Microbiology & Infectious Diseases (2019) 38:1395–1408 https://doi.org/10.1007/s10096-019-03548-5 REVIEW A review of melioidosis cases imported into Europe Sarah Le Tohic1 & Marc Montana2,3 & Lionel Koch4 & Christophe Curti2,5 & Patrice Vanelle 2,5 Received: 8 February 2019 /Accepted: 25 March 2019 /Published online: 4 April 2019 # Springer-Verlag GmbH Germany, part of Springer Nature 2019 Abstract Melioidosis is a tropical bacterial infection, rarely encountered, and poorly known by clinicians. In non-endemic areas, a misdiagnosis can lead to a fatal outcome. This study aims to identify the main characteristics of imported and diagnosed melioidosis cases in Europe to increase clinician’s awareness of this diagnosis. A literature review of imported and diagnosed human melioidosis cases in Europe was performed. PubMed and Web of Science search engines were used for retrieving articles from 2000 to November 2018. Seventy-seven cases of imported melioidosis into Europe described in the literature were identified. More than half of the cases were acquired in Thailand (53%) by men (73%). Patients were usually exposed to Burkholderia pseudomallei during a holiday stay (58%) of less than 1 month (23%) and were hospitalized during the month following their return to Europe (58%). Among travelers, melioidosis is less often associated with risk factor (16%), diabetes being the most frequently comorbidity related (19%). The clinical presentation was multifaceted, pneumonia being the most common symptom (52%), followed by cardiovascular form (45%) and skin and soft tissues damages (35%). The diagnosis was obtained by culture (92%), often supplemented by morphological, biochemical, and molecular identification (23%). Misdiagnoses were common (21%). Over half of the patients received a complete and adapted treatment (56%). Mortality is lower for returning traveler (6%). Imported melioidosis cases into Europe have their own characteristics. This possibility should be considered in patients with pneumonia, fever, and/or abscess returning from endemic areas even years after. Keywords Melioidosis . Pneumonia . Travel medicine . Case reports Introduction Melioidosis is a tropical bacterial infection, caused by a bacil- Electronic supplementary material The online version of this article lus Burkholderia pseudomallei, formerly known as (https://doi.org/10.1007/s10096-019-03548-5) contains supplementary Pseudomonas pseudomallei, Malleomyces pseudomallei,or material, which is available to authorized users. Bacillus whitmori. Each year, there are nearly 165,000 cases worldwide and 54% are estimated to be fatal [1]. The mortal- * Sarah Le Tohic ity burden is similar to that of measles [2]. Melioidosis is [email protected] endemic in Southeast Asia, Northern Australia, India, and China. This disease sporadically occurs in tropical areas be- 1 ’ Hôpital d Instruction des Armées Laveran, Marseille, France tween the 20th of northern and southern parallels [3]. 2 Laboratoire de Pharmaco-Chimie Radicalaire, Aix Marseille Univ, Melioidosis is extremely rare in the temperate zone: they are CNRS, ICR, Marseille, France, Marseille, France essentially imported cases by travelers or immigrants [4]. But 3 Assistance Publique-Hôpitaux de Marseille (AP-HM), Oncopharma, global warming and mass international travel in Asia can in- Hôpital Nord, Marseille, France crease the incidence in non-endemic areas [2]. 4 Institut de Recherche Biomédicale des Armées (IRBA), Pseudomonas pseudomallei is an environmental Gram- Brétigny-sur-Orge, France negative bacterium found in soil and surface water, especially 5 Service central de la qualité et de l’information pharmaceutiques during the rainy season. Community-acquired infections in (SCQIP), Assistance Publique-Hôpitaux de Marseille (AP-HM), human results from exposure through wounded skin, inhala- Marseille, France tion, or ingestion. Nosocomial infections have been rarely 1396 Eur J Clin Microbiol Infect Dis (2019) 38:1395–1408 reported [5]. Melioidosis is not considered to be a contagious of Science (Thomson Reuters Scientific—https://www. infection and human-to-human transmission is very rare [3, 5]. webofknowledge.com/) to identify all published case reports This emerging disease is pleomorphic and opportunistic of melioidosis imported in humans into Europe. The literature because it can affect various organs and displays different search included English-, German-, and French-language ar- clinical presentations from chronic disease to sepsis and death. ticles and publications in other languages if informative ab- Nevertheless, the leading form of melioidosis is pulmonary stracts in the English language were available. disease, as this pathogenic agent is unknown in non-endemic Search terms were selected to detect case reports published areas and it can be easily mistaken for other diseases, such as about imported melioidosis applying exclusion criteria. The community-acquired pneumonia or tuberculosis. So, it is often following terms combinations were applied: Bmelioidosis^ referred to as Bthe Great Mimicker^ [4]andremains OR BBurkholderia pseudomallei^ OR BPseudomonas underdiagnosed. The first diagnosis is based on biochemical pseudomallei^ OR BMalleomyces pseudomallei^ OR tests and morphology identification of bacterium. Molecular BWithmore bacillus^ in human. The Boolean operators were biology is also essential to limit the risk of confusion but takes varied according to the rules of each specific database. longer to obtain. However, early diagnosis and treatment are Searches were conducted using the final limit dates of crucial to reduce mortality, which may reach up to 87% with- January 1, 2000 and November 15, 2018. out treatment [6]. Currently, no vaccine is available and Pseudomonas pseudomallei is widely resistant to several an- Study selection tibiotics, such as gentamicin, colistin, and rifampicin. The bacterium is most often susceptible to ceftazidime, The review was performed in two main stages, as described by meropenem, and amoxicillin–clavulanate. Matos [11]. Eligibility criteria were predetermined by the au- In most European countries, melioidosis is not a nationally thors (Table 1). In the first step, they independently reviewed notifiable disease, making it difficult to ensure epidemiologi- the titles and abstracts yielded by this comprehensive search cal surveillance. However, Pseudomonas pseudomallei is a and subsequently selected articles based on the predetermined selected agent according to the US federal law and belongs inclusion criteria. Any reservations on eligibility for inclusion to Tier 1 agent list of the Centers for Diseases Control and were resolved by discussion between reviewers. After remov- Prevention (CDC). In France, the possession of this organism al of duplicates, the authors read each selected full text and is subject to the regulation on highly pathogenic microorgan- eliminated articles fitting the exclusion criteria. During this isms and toxins (MOT) and must be handled in a biosafety second stage, the references of relevant articles were exam- level 3 laboratory. All these rules and regulations are ex- ined to identify additional cases not found in computerized plained by the high pathogenicity of the bacteria and by its databases. possible use as bioterrorism agent [7–9]. Melioidosis has the potential to become a real public health Data extraction process problem, considering its rising incidence, misdiagnosis, ther- apeutic difficulties, high mortality, and induced biological risk The data collected from all included studies are as follows: [2, 7, 10]. So, we decided to conduct a systematic review of year and country of diagnosis or publication, basic demo- melioidosis cases imported and diagnosed in human in Europe graphic characteristics (age, gender, ethnicity, and socio- since 2000 to increase clinicians’ awareness of its diagnosis. professional category), underlying diseases, foreign travel his- tory (type, country, and duration (< 1 month, 1–6months,> 6months[4], or unknown)), route of exposure, manifestations Materials and methods and care in endemic area, time between arrival in Europe and hospitalization (< 1 month, 1–6 months, > 6 months [4], or Background definitions unknown), clinical manifestations (included fever, pulmonary symptoms, weightless [12],, abscess and localization, bacter- The search method employed in this systematic review was to emia), source of the B. pseudomallei isolates, method used identify and select case reports of imported melioidosis in (phenotype, molecular biology, spectrometry), complementa- humans in Europe. Information on clinical characteristics, ex- ry examinations, researched pathogen agents and misdiagno- posure history, comorbidities, management, and outcome sis, treatments and duration, observed adverse effects, resis- were abstracted. tance to recommended antibiotics, length of follow-up, and outcome (cure, recurrence, death, and unknown). Data sources and searches Morphological and biochemical identification (VITEK 1 and 2, API 20 NE (bioMérieux, Marcy l’Etoile, France)) are We searched MEDLINE/PubMed (National Library of grouped under the name of the phenotype. Molecular biology Medicine—https://www.ncbi.nlm.nih.gov/pubmed)andWeb includes sequencing of 16SrRNA, PCR (polymerase chain Eur J Clin Microbiol Infect Dis (2019) 38:1395–1408 1397 Table 1 Inclusion and exclusion criteria Parameter Inclusion Exclusion 1 Language German, English, French, other languages if Any other
Load more

Recommended publications
  • Infectious Disease
    INFECTIOUS DISEASE Infectious diseases are caused by germs that are transmitted directly from person to NOTE: person; animal to person (zoonotic The following symbols are used throughout this Community Health Assessment Report to serve only as a simple and quick diseases); from mother to unborn child; or reference for data comparisons and trends for the County. indirectly, such as when a person touches Further analysis may be required before drawing conclusions about the data. a surface that some germs can linger on. The NYSDOH recommends several The apple symbol represents areas in which Oneida County’s status or trend is FAVORABLE or COMPARABLE to its effective strategies for preventing comparison (i.e., NYS, US) or areas/issues identified as infectious diseases,, including: ensuring STRENGTHS. procedures and systems are in place in The magnifying glass symbols represent areas in which Oneida County’s status or trend is UNFAVORABLE to its communities for immunizations to be up to comparison (i.e., NYS, US) or areas/issues of CONCERN date; enabling sanitary practices by or NEED that may warrant further analysis. conveniently located sinks for washing DATA REFERENCES: hands; influencing community resources • All References to tables are in Attachment A – Oneida County Data Book. and cultures to facilitate abstinence and • See also Attachment B – Oneida County Chart Book for risk reduction practices for sexual behavior additional data. and injection drug use, and setting up support systems to ensure medicines are taken as prescribed.453 The reporting of suspect or confirmed communicable diseases is mandated under the New York State Sanitary Code (10NYCRR 2.10).
    [Show full text]
  • Melioidosis: an Emerging Infectious Disease
    Review Article www.jpgmonline.com Melioidosis: An emerging infectious disease Raja NS, Ahmed MZ,* Singh NN** Department of Medical ABSTRACT Microbiology, University of Malaya Medical Center, Kuala Lumpur, Infectious diseases account for a third of all the deaths in the developing world. Achievements in understanding Malaysia, *St. the basic microbiology, pathogenesis, host defenses and expanded epidemiology of infectious diseases have Bartholomew’s Hospital, resulted in better management and reduced mortality. However, an emerging infectious disease, melioidosis, West Smithfield, London, is becoming endemic in the tropical regions of the world and is spreading to non-endemic areas. This article UK and **School of highlights the current understanding of melioidosis including advances in diagnosis, treatment and prevention. Biosciences, Cardiff Better understanding of melioidosis is essential, as it is life-threatening and if untreated, patients can succumb University, Cardiff, UK to it. Our sources include a literature review, information from international consensus meetings on melioidosis Correspondence: and ongoing discussions within the medical and scientific community. N. S. Raja, E-mail: [email protected] Received : 21-2-2005 Review completed : 20-3-2005 Accepted : 30-5-2005 PubMed ID : 16006713 KEY WORDS: Melioidosis, Burkholderia pseudomallei, Infection J Postgrad Med 2005;51:140-5 he name melioidosis [also known as Whitmore dis- in returning travellers to Europe from endemic areas.[14] The T ease] is taken from the Greek word ‘melis’ meaning geographic area of the prevalence of the organism is bound to distemper of asses and ‘eidos’ meaning resembles glanders. increase as the awareness increases. Melioidosis is a zoonotic disease caused by Pseudomonas pseudomallei [now known as Burkholderia pseudomallei], a B.
    [Show full text]
  • Chlamydia-English
    URGENT and PRIVATE IMPORTANT INFORMATION ABOUT YOUR HEALTH DIRECTIONS FOR SEX PARTNERS OF PERSONS WITH CHLAMYDIA PLEASE READ THIS VERY CAREFULLY Your sex partner has recently been treated for chlamydia. Chlamydia is a sexually transmitted disease (STD) that you can get from having any kind of sex (oral, vaginal, or anal) with a person who already has it. You may have been exposed. The good news is that it’s easily treated. You are being given a medicine called azithromycin (sometimes known as “Zithromax”) to treat your chlamydia. Your partner may have given you the actual medicine, or a prescription that you can take to a pharmacy. These are instructions for how to take azithromycin. The best way to take care of this infection is to see your own doctor or clinic provider right away. If you can’t get to a doctor in the next several days, you should take the azithromycin. Even if you decide to take the medicine, it is very important to see a doctor as soon as you can, to get tested for other STDs. People can have more than one STD at the same time. Azithromycin will not cure other sexually transmitted infections. Having STDs can increase your risk of getting HIV, so make sure to also get an HIV test. SYMPTOMS Some people with chlamydia have symptoms, but most do not. Symptoms may include pain in your testicles, pelvis, or lower part of your belly. You may also have pain when you urinate or when having sex. Many people with chlamydia do not know they are infected because they feel fine.
    [Show full text]
  • Cutaneous Manifestations of HIV Infection Carrie L
    Chapter Title Cutaneous Manifestations of HIV Infection Carrie L. Kovarik, MD Addy Kekitiinwa, MB, ChB Heidi Schwarzwald, MD, MPH Objectives Table 1. Cutaneous manifestations of HIV 1. Review the most common cutaneous Cause Manifestations manifestations of human immunodeficiency Neoplasia Kaposi sarcoma virus (HIV) infection. Lymphoma 2. Describe the methods of diagnosis and treatment Squamous cell carcinoma for each cutaneous disease. Infectious Herpes zoster Herpes simplex virus infections Superficial fungal infections Key Points Angular cheilitis 1. Cutaneous lesions are often the first Chancroid manifestation of HIV noted by patients and Cryptococcus Histoplasmosis health professionals. Human papillomavirus (verruca vulgaris, 2. Cutaneous lesions occur frequently in both adults verruca plana, condyloma) and children infected with HIV. Impetigo 3. Diagnosis of several mucocutaneous diseases Lymphogranuloma venereum in the setting of HIV will allow appropriate Molluscum contagiosum treatment and prevention of complications. Syphilis Furunculosis 4. Prompt diagnosis and treatment of cutaneous Folliculitis manifestations can prevent complications and Pyomyositis improve quality of life for HIV-infected persons. Other Pruritic papular eruption Seborrheic dermatitis Overview Drug eruption Vasculitis Many people with human immunodeficiency virus Psoriasis (HIV) infection develop cutaneous lesions. The risk of Hyperpigmentation developing cutaneous manifestations increases with Photodermatitis disease progression. As immunosuppression increases, Atopic Dermatitis patients may develop multiple skin diseases at once, Hair changes atypical-appearing skin lesions, or diseases that are refractory to standard treatment. Skin conditions that have been associated with HIV infection are listed in Clinical staging is useful in the initial assessment of a Table 1. patient, at the time the patient enters into long-term HIV care, and for monitoring a patient’s disease progression.
    [Show full text]
  • Pdf/Bookshelf NBK368467.Pdf
    BMJ 2019;365:l4159 doi: 10.1136/bmj.l4159 (Published 28 June 2019) Page 1 of 11 Practice BMJ: first published as 10.1136/bmj.l4159 on 28 June 2019. Downloaded from PRACTICE CLINICAL UPDATES Syphilis OPEN ACCESS Patrick O'Byrne associate professor, nurse practitioner 1 2, Paul MacPherson infectious disease specialist 3 1School of Nursing, University of Ottawa, Ottawa, Ontario K1H 8M5, Canada; 2Sexual Health Clinic, Ottawa Public Health, Ottawa, Ontario K1N 5P9; 3Division of Infectious Diseases, Ottawa Hospital General Campus, Ottawa, Ontario What you need to know Box 1: Symptoms of syphilis by stage of infection (see fig 1) • Incidence rates of syphilis have increased substantially around the Primary world, mostly affecting men who have sex with men and people infected • Symptoms appear 10-90 days (mean 21 days) after exposure with HIV http://www.bmj.com/ • Main symptom is a <2 cm chancre: • Have a high index of suspicion for syphilis in any sexually active patient – Progresses from a macule to papule to ulcer over 7 days with genital lesions or rashes – Painless, solitary, indurated, clean base (98% specific, 31% sensitive) • Primary syphilis classically presents as a single, painless, indurated genital ulcer (chancre), but this presentation is only 31% sensitive; – On glans, corona, labia, fourchette, or perineum lesions can be painful, multiple, and extra-genital – A third are extragenital in men who have sex with men and in women • Diagnosis is usually based on serology, using a combination of treponemal and non-treponemal tests. Syphilis remains sensitive to • Localised painless adenopathy benzathine penicillin G Secondary on 24 September 2021 by guest.
    [Show full text]
  • WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/05 (2006.01) A61P 31/02 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/CA20 14/000 174 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 4 March 2014 (04.03.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 13/790,91 1 8 March 2013 (08.03.2013) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: LABORATOIRE M2 [CA/CA]; 4005-A, rue kind of regional protection available): ARIPO (BW, GH, de la Garlock, Sherbrooke, Quebec J1L 1W9 (CA). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: LEMIRE, Gaetan; 6505, rue de la fougere, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Sherbrooke, Quebec JIN 3W3 (CA).
    [Show full text]
  • 2020 European Guideline on the Management of Syphilis
    DOI: 10.1111/jdv.16946 JEADV GUIDELINES 2020 European guideline on the management of syphilis M. Janier,1,* M. Unemo,2 N. Dupin,3 G.S. Tiplica,4 M. Potocnik, 5 R. Patel6 1STD Clinic, Hopital^ Saint-Louis AP-HP and Hopital^ Saint-Joseph, Paris, France 2WHO Collaborating Centre for Gonorrhoea and other Sexually Transmitted Infections, Department of Laboratory Medicine, Microbiology, Orebro€ University Hospital and Orebro€ University, Orebro,€ Sweden 3Syphilis National Reference Center, Hopital^ Tarnier-Cochin, AP-HP, Paris, France 42nd Dermatological Clinic, Carol Davila University, Colentina Clinical Hospital, Bucharest, Romania 5Department of Dermatovenereology, University Medical Centre Ljubljana, Ljubljana, Slovenia 6Department of Genitourinary Medicine, the Royal South Hants Hospital, Southampton, UK *Correspondence to: M. Janier. E-mail: [email protected] Abstract The 2020 edition of the European guideline on the management of syphilis is an update of the 2014 edition. Main modifications and updates include: - The ongoing epidemics of early syphilis in Europe, particularly in men who have sex with men (MSM) - The development of dual treponemal and non-treponemal point-of-care (POC) tests - The progress in non-treponemal test (NTT) automatization - The regular episodic shortage of benzathine penicillin G (BPG) in some European countries - The exclusion of azithromycin as an alternative treatment at any stage of syphilis - The pre-exposure or immediate post-exposure prophylaxis with doxycycline in populations at high risk of acquiring syphilis. Received: 12 June 2020; Accepted: 4 September 2020 Conflicts of interest The authors have no conflicts of interest related to this guideline. Funding sources None. Introduction EEA countries and particularly among men who have sex with Syphilis is a systemic human disease due to Treponema pallidum men (MSM).3 subsp.
    [Show full text]
  • Reportable Disease Surveillance in Virginia, 2013
    Reportable Disease Surveillance in Virginia, 2013 Marissa J. Levine, MD, MPH State Health Commissioner Report Production Team: Division of Surveillance and Investigation, Division of Disease Prevention, Division of Environmental Epidemiology, and Division of Immunization Virginia Department of Health Post Office Box 2448 Richmond, Virginia 23218 www.vdh.virginia.gov ACKNOWLEDGEMENT In addition to the employees of the work units listed below, the Office of Epidemiology would like to acknowledge the contributions of all those engaged in disease surveillance and control activities across the state throughout the year. We appreciate the commitment to public health of all epidemiology staff in local and district health departments and the Regional and Central Offices, as well as the conscientious work of nurses, environmental health specialists, infection preventionists, physicians, laboratory staff, and administrators. These persons report or manage disease surveillance data on an ongoing basis and diligently strive to control morbidity in Virginia. This report would not be possible without the efforts of all those who collect and follow up on morbidity reports. Divisions in the Virginia Department of Health Office of Epidemiology Disease Prevention Telephone: 804-864-7964 Environmental Epidemiology Telephone: 804-864-8182 Immunization Telephone: 804-864-8055 Surveillance and Investigation Telephone: 804-864-8141 TABLE OF CONTENTS INTRODUCTION Introduction ......................................................................................................................................1
    [Show full text]
  • Rheumatic Manifestations of Bartonella Infection in 2 Children MOHAMMAD J
    Case Report Rheumatic Manifestations of Bartonella Infection in 2 Children MOHAMMAD J. AL-MATAR, ROSS E. PETTY, DAVID A. CABRAL, LORI B. TUCKER, BANAFSHI PEYVANDI, JULIE PRENDIVILLE, JACK FORBES, ROBYN CAIRNS, and RALPH ROTHSTEIN ABSTRACT. We describe 2 patients with very unusual rheumatological presentations presumably caused by Bartonella infection: one had myositis of proximal thigh muscles bilaterally, and the other had arthritis and skin nodules. Both patients had very high levels of antibody to Bartonella that decreased in asso- ciation with clinical improvement. Bartonella infection should be considered in the differential diag- nosis of unusual myositis or arthritis in children. (J Rheumatol 2002;29:184–6) Key Indexing Terms: MYOSITIS ARTHRITIS BARTONELLA Infection with Bartonella species has a wide range of mani- was slightly increased at 9.86 IU/l (normal 4.51–9.16), and IgA was 2.1 IU/l festations in children including cat scratch disease (regional (normal 0.2–1.0). C3 was 0.11 g/l (normal 0.77–1.43) and C4 was 0.28 (nor- mal 0.07–0.40). Antinuclear antibodies were present at a titer of 1:40, the anti- granulomatous lymphadenitis), bacillary angiomatosis, streptolysin O titer was 35 (normal < 200), and the anti-DNAase B titer was encephalitis, Parinaud’s oculoglandular syndrome, Trench 1:85 (normal). Urinalysis showed 50–100 erythrocytes and 5–10 leukocytes fever (Vincent’s angina), osteomyelitis, granulomatous per high power field. Routine cultures of urine, blood, and throat were nega- hepatitis, splenitis, pneumonitis, endocarditis, and fever of tive. Liver enzymes, electrolytes, HIV serology, cerebrospinal fluid analysis, unknown origin1-3.
    [Show full text]
  • Leptospirosis: a Waterborne Zoonotic Disease of Global Importance
    August 2006 volume 22 number 08 Leptospirosis: A waterborne zoonotic disease of global importance INTRODUCTION syndrome has two phases: a septicemic and an immune phase (Levett, 2005). Leptospirosis is considered one of the most common zoonotic diseases It is in the immune phase that organ-specific damage and more severe illness globally. In the United States, outbreaks are increasingly being reported is seen. See text box for more information on the two phases. The typical among those participating in recreational water activities (Centers for Disease presenting signs of leptospirosis in humans are fever, headache, chills, con- Control and Prevention [CDC], 1996, 1998, and 2001) and sporadic cases are junctival suffusion, and myalgia (particularly in calf and lumbar areas) often underdiagnosed. With the onset of warm temperatures, increased (Heymann, 2004). Less common signs include a biphasic fever, meningitis, outdoor activities, and travel, Georgia may expect to see more leptospirosis photosensitivity, rash, and hepatic or renal failure. cases. DIAGNOSIS OF LEPTOSPIROSIS Leptospirosis is a zoonosis caused by infection with the bacterium Leptospira Detecting serum antibodies against leptospira interrogans. The disease occurs worldwide, but it is most common in temper- • Microscopic Agglutination Titers (MAT) ate regions in the late summer and early fall and in tropical regions during o Paired serum samples which show a four-fold rise in rainy seasons. It is not surprising that Hawaii has the highest incidence of titer confirm the diagnosis; a single high titer in a per- leptospirosis in the United States (Levett, 2005). The reservoir of pathogenic son clinically suspected to have leptospirosis is highly leptospires is the renal tubules of wild and domestic animals.
    [Show full text]
  • Gonorrhea, Chlamydia, and Syphilis
    2019 GONORRHEA, CHLAMYDIA, AND SYPHILIS AND CHLAMYDIA, GONORRHEA, Dedication TAG would like to thank the National Coalition of STD Directors for funding and input on the report. THE PIPELINE REPORT Pipeline for Gonorrhea, Chlamydia, and Syphilis By Jeremiah Johnson Introduction The current toolbox for addressing gonorrhea, chlamydia, and syphilis is inadequate. At a time where all three epidemics are dramatically expanding in locations all around the globe, including record-breaking rates of new infections in the United States, stakeholders must make do with old tools, inadequate systems for addressing sexual health, and a sparse research pipeline of new treatment, prevention, and diagnostic options. Lack of investment in sexual health research has left the field with inadequate prevention options, and limited access to infrastructure for testing and treatment have allowed sexually transmitted infections (STIs) to flourish. The consequences of this underinvestment are large: according to the World Health Organization (WHO), in 2012 there were an estimated 357 million new infections (roughly 1 million per day) of the four curable STIs: gonorrhea, chlamydia, syphilis, and trichomoniasis.1 In the United States, the three reportable STIs that are the focus of this report—gonorrhea, chlamydia, and syphilis—are growing at record paces. In 2017, a total of 30,644 cases of primary and secondary (P&S) syphilis—the most infectious stages of the disease—were reported in the United States. Since reaching a historic low in 2000 and 2001, the rate of P&S syphilis has increased almost every year, increasing 10.5% during 2016–2017. Also in 2017, 555,608 cases of gonorrhea were reported to the U.S.
    [Show full text]
  • Syphilis NSW Control Guideline for Public Health Units
    Syphilis NSW Control Guideline for Public Health Units Revision history Version Date Revised by Changes Approval 1.0 01/06/2015 CDWG Revision CDNA/AHPPC 1.1 01/08/2016 CDB Case definition CHO 2.0 09/2016 CDB Update to align with the Syphilis Series of CHO National Guidelines (SoNG) v1.0 (endorsed 15 Jan 2015, released 21 Aug 2016), localised for NSW as indicated by [hard brackets]. 3.0 20/03/2019 CDB Update to align with the Syphilis Series of CHO National Guidelines (SoNG) v1.1 (endorsed 17 July 2018, released 03 Aug 2018), localised for NSW as indicated by [hard brackets]. 4.0 04/10/2019 CDB Update to implement timely follow-up of all CHO women of reproductive age in line with changing epidemiological trends in NSW as indicated by [hard brackets] 4.1 13/05/2021 CDB Updated to align with National Syphilis CHO (congenital) case definition v1.3 (endorsed 24 September 2020, implemented 1 January 2021, published 13 January 2021) 1. Summary ........................................................................................................................ 2 2. The disease ..................................................................................................................... 3 3. Routine prevention activities ............................................................................................. 5 4. Surveillance objectives ..................................................................................................... 5 5. Data management ..........................................................................................................
    [Show full text]